Safety and Performance of INVICTA Ventricular DF4 LEADS With Active Fixation-(APOLLO)

APOLLO study is a pre-market approval (INVICTA leads - devices under investigation - are not CE marked), interventional, prospective, longitudinal, international (European), multicenter, single arm study.

The devices under investigation, the INVICTA defibrillation leads, are new quadripolar leads, to be used with Implantable Cardiac Defibrillators and Cardiac Resynchronization Therapy Defibrillators (ICD/CRT-D).

This clinical study intends to demonstrate safety and electrical performances of the INVICTA leads among the different models: active fixation either single coil (model 1CR) or dual coil (model 2CR)leads models. The clinical data will be used to support the application to CE marking of INVICTA leads.

The primary endpoints will be evaluated at 3 months post-implantation; secondary endpoints will be evaluated up to 2 years post-implantation.

A total number of 445 patients will be enrolled in the study, in up to 60 centers in Europe.

The follow-up visits are scheduled at hospital discharge, at 1 month, at 3 months, at 6 months, at 12 months, at 18 months and at 24 months, post-implant

Inclusion criteria

• Any patient presenting an ICD or CRT-D indication as detailed in the latest ESC guidelines
• Scheduled for a de-novo implant of an ICD (VR, DR) or CRT-D, manufactured by MicroPort CRM and equipped with a DF4 connector
• Signed and dated informed consent

Exclusion criteria

• Tricuspid valvular disease or any type of tricuspid replacement heart valve (mechanical or tissue)
• Transient tachyarrhythmias due to reversible causes (such as drug intoxication, electrolyte imbalance, sepsis, hypoxia or other factors as myocardial infarction or electric shock)
• Contraindication to a maximum single dose of 330 µg dexamethasone sodium phosphate (DSP)
• Active myocarditis
• Previous implant of pacemaker, ICD or CRT-D device and leads
• Currently enrolled or planning to participate in a potentially confounding drug or device trial during the course of this study
• Incapacitated subject or under guardianship, inability to understand the purpose of the study, or to meet follow-up visits at the implanting centre as defined in the investigational plan
• Minor subjects
• Pre-menopausal women
• Drug addiction or abuse
• Life expectancy less than 1 year